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Abstract
Background: Surgical treatment options of femoral metastases include intramedullary nailing (IMN) and endoprosthetic
reconstruction (EPR). Previous studies have demonstrated functional and oncological advantages of EPR over
IMN. The purpose of this study was to (1) report the durability of IMN and (2) establish the indication of IMN
for femoral metastases.
Methods: In 2003–2013, among 186 surgically treated femoral metastasis cases, we retrospectively reviewed
80 consecutive IMN cases in 75 patients, including 14 pathological and 66 impending fractures. For the decision
of surgical procedure (IMN, EPR, or plating), the following factors are considered: (1) fracture pattern (impending
or pathological fracture), (2) Mirels’ score (≥8 or <8), (3) fracture site (femoral head, neck, intertrochanter, subtrochanter,
diaphysis, or distal), (4) number of metastases (solitary or multiple), and (5) patient’s estimated prognosis. Patient
demographics, postoperative survival, implant survival, and early postoperative mortality were reviewed.
Results: The patients were 37 males and 38 females, with a mean age of 60.1 (20–84) years. Average follow-up period
was 11.4 (1–77) months. The most common fracture site was the subtrochanter (46/80), followed by the diaphysis (26/80)
and the intertrochanter (8/80). The most common primary tumor was lung cancer (24/80, 32 %), followed by
breast cancer (24 %) and melanoma (15 %). With the exception of six cases, all patients underwent postoperative
radiotherapy to the affected whole femur. The postoperative patient survival was 14.2 and 8.4 % at 2 and 3 years
from surgery, respectively, while the implant survival rate remained 94.0 % at both 2 and 3 years. Three out of 46
subtrochanteric cases required revision surgeries because of proximal breakage of implant 4–50 months after initial
surgery for femoral metastases, but all were replaced by mega-prosthesis and did not need further operation until their
death. Early postoperative fatal complications were observed in three patients, all of which were pulmonary dysfunction.
Conclusions: The performance of IMN in this study was satisfactory although a large portion of sub- and intertrochanter
metastases were included. Broader indication including these parts should be considered, for IMN has advantages such as
lower cost and less invasiveness and even an implant failure can be revised by mega-prosthetic reconstruction.
Keywords: Metastatic femoral fracture, Intramedullary nailing, Postoperative survival, Implant survival
Background
The femur is one of the most common sites for bone
metastases [1, 2]. Metastatic femoral fracture affects not
only a patient’s prognosis but also their quality of life
and ambulation [3–5]. Surgical procedures for femoral
metastases are widely chosen from intramedullary nailing
(IMN) [6–16], endoprosthetic reconstruction (EPR) [7–14],
or plating and cementation [7, 8, 11, 12], but how to choose
the best treatment for each case is still uncertain, especially
for inter- and subtrochanteric metastases [8, 9, 14, 15].
Some previous studies demonstrated that the rate of im-
plant failure in the EPR group was lower than that in the
IMN group, and overall patient survival was also longer
for the EPR group than the IMN group [9–11]. However,
it is impossible to remove any treatment bias related to
the patient’s general condition and primary tumor before
the procedure for both groups in such studies. By contrast,
IMN has some advantages over EPR, including lower cost
and less invasiveness. Considering these benefits, if IMN
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is durable throughout the expected lifespan for patients
with metastases, IMN can become a primary surgical op-
tion for patients affected by femoral metastases.
The aim of this study was to (1) accurately measure
the implant survival of IMN at our institution and (2)
reconsider the indication of IMN for femoral meta-
static lesions.
Methods
In our institution, before the decision of surgery and pro-
cedure type (IMN, EPR, or plating), several factors are
considered, (1) fracture pattern (impending or patho-
logical fracture), (2) fracture risk (Mirels’ score of ≥8 or <8
[17]) for impending fracture, (3) fracture site (femoral
head, neck, intertrochanter, subtrochanter, diaphysis, or
distal), (4) number of metastases (solitary or multiple), (5)
patient’s estimated prognosis (≥6 or <6 months), and (6)
patient’s preference after informed consent. A flowchart in
Fig. 1 demonstrates our strategy concerning the proced-
ural selection. IMN was performed with either the Trigen
System (Smith & Nephew, Memphis, TN, USA) or the
Alta CFx IM rod system (Howmedica, Rutherford, NJ,
USA). Among IMN procedures, the patients routinely
underwent postoperative radiotherapy to the affected
whole femur at approximately 2 weeks after the surgery.
According to the database at our institution, 186 sur-
geries for femoral metastases with pathological or
impending fracture were identified over a 10-year
period, from June 2003 to June 2013. Among the 186
cases, there were 95 EPR, 80 IMN, 8 plating and screw
with cementation, and 3 Girdlestone procedures. The 80
consecutive IMN procedures in 75 patients (37 males
and 38 females) were retrospectively reviewed in terms
of patient demographic data, postoperative survival, im-
plant survival, and early fatal postoperative complica-
tions. Postoperative survival was calculated from the
date of administering IMN procedure to the date of
death or last follow-up. Implant survival was defined
from the date of administering IMN procedure to the
date of implant failure, death, or last follow-up. The
average age and follow-up period were 60.1 years (20–
80 years) and 11.4 months (1–77 months), respectively.
Impending fractures accounted for 82.5 % (66 of 80) and
pathological fractures made up 17.5 % (14 of 80). The
majority of the cases had multiple metastases (74 of 80,
92.5 %). Ten percent of the lesions (8 of 80) occurred in
the intertrochanteric area, 57.5 % (46 of 80) in the sub-
trochanteric area, and 32.5 % (26 of 80) in the shaft of
femur. The most common primary tumor was lung can-
cer (32.0 %, 24 of 80), followed by breast cancer (24.0 %,
18 of 80) (Table 1).
Kaplan-Meier survival curves using postoperative survival
and implant survival were calculated using IBM SPSS ver-
sion 17.0 (SPSS Inc., Chicago, IL, USA). The event for
postoperative survival and implant survival is death and im-
plant failure, respectively.
Results and discussion
The patient background is summarized in Table 1. Eighty
IMN procedures were performed in 75 patients, 37 males
and 38 females. Five patients underwent bilateral IMN in
separate procedures at least 8 days apart. Seventy-four
cases underwent radiotherapy after IMN procedure; how-
ever, six out of 80 cases were unable to undergo radiother-
apy due to postoperative poor medical problems (Table 1).
The 2- and 3-year postoperative survivals were 14.2
and 8.4 %, respectively (Fig. 2a). In contrast, the implant
survival rate was 94.0 % at both 2 and 3 years; however,
it dropped to 62.8 % at 50 months (Fig. 2b).
Fig. 1 Flowchart of our institutional strategy for procedural selection.
For the decision of surgical procedure (IMN or EPR), the following
factors are considered: (1) fracture pattern (impending or pathological
fracture), (2) Mirels’ score (≥8 or <8), (3) fracture site (femoral head,
neck, intertrochanter, subtrochanter, diaphysis, or distal), (4) number of
metastases (solitary or multiple), and (5) patient’s estimated prognosis.
IMN intramedullary nailing, EPR endoprosthetic reconstruction, Fx
fracture, RT radiotherapy, CT chemotherapy, BP bisphosphonate
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In this study, three intramedullary nails broke through
their proximal parts (Table 2). For all three patients, the
fracture site was subtrochanteric and the implant failures
showed a similar pattern of breakage at the proximal
part of the IM rod. The IM rods were removed in all
three cases, and the proximal part of the femurs were
resected and then replaced with EPRs. The three
patients did not require any further operations until
death. Figure 3 shows the clinical course of case 2
patient who was a 49-year female and had a 5-year history
of breast cancer, who presented with severe left femoral
pain, and the patient Mirels’ score was 10. The patient
underwent IMN procedure for impending fracture. Fifty
months after the first surgery, she underwent EPR as a re-
vision surgery due to implant breakage. The patient did
not require any further operations until she died after
1.5 months. Table 3 shows three early postoperative
deaths on postoperative days 3, 7, and 12. Two of the
three patients (cases 1 and 3) underwent palliative therapy
before the surgery, but complained of severe femoral pain
with Mirels’ score of 10. One patient (case 2) was trans-
ferred to the emergency department due to pathological
fracture. All the patients had several comorbidities in-
cluding lung, liver, adrenal, brain, and multiple bone
metastases, and the cause of death in all three cases
were respiratory failure (Table 3).
The goal of surgical treatment of femoral metastatic frac-
tures is not only to internally fix or prevent pathological
fracture but also to reduce pain and optimize recovery, mo-
bility, or care for the patient with minimal invasiveness and
complications [3–5, 14]. The strategy is to ensure the dur-
ability of treatment, and in this regard, implant survival
should exceed patient survival after surgery.
Our study has several potential limitations. Firstly, this
study is a single-center retrospective study with all the
limitations inherent to such design. Secondly, there were
Fig. 2 Survival curve for postoperative and implant survival. Kaplan-Meier survival analysis shows for postoperative survival (a) and implant survival (b)
Table 1 Patient characteristics for IMN
Characteristics IMN
Number of patients 75 (37 males/38 females)
Number of cases 80 (38 males/42 females)
Average ages (year) 60.1 (range, 20–80)
Average follow up (months) 11.4 (range, 1–77)
Fracture pattern
Impending 66 (82.5 %)
Survival (<6 months/>6 months) 35 (53 %)/31 (47 %)
Pathological 14 (17.5 %)
Survival (<6 months/>6 months) 6 (42.9 %)/8 (57.1 %)
Number of metastases
Solitary 6 (7.5 %)
Survival (<6 months/>6 months) 1 (16.7 %)/5 (83.3 %)
Multiple 74 (92.5 %)
Survival (<6 months/>6 months) 40 (54.1 %)/34 (45.9 %)
Site of metastasis
Head/neck 0 (0 %)
Intertrochanteric 8 (10 %)
Subtrochanteric 46 (57.5 %)
Diaphysis 26 (32.5 %)
Primary tumor
Lung 24 (32.0 %)
Breast 18 (24.0 %)
Melanoma 11 (14.7 %)
Renal 5 (6.7 %)
Prostate 5 (6.7 %)
Unknown 4 (5.3 %)
Others 8 (10.6 %)
Radiotherapy
Yes 74 (92.5 %)
No 6 (7.5 %)
IMN intramedullary nailing
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some metastatic femoral fracture cases that were not
treated according the indication pathway because of sur-
geon and patient preferences. Thirdly, patients with me-
tastases underwent not only surgery but also adjuvant
therapies, such as chemotherapy, radiotherapy, and hor-
monal therapy. Postoperative survival may be affected by
those therapies. However, in this study, there were 186
consecutive procedures for metastatic femoral fractures,
and 80 IMN cases, suggesting a degree of external validity
and robustness.
Surgical treatment strategy towards femoral metastases
still remains unclear. Both IMN and EPR for femoral
metastases are widely performed. IMN has some advan-
tages over EPR, such as lower cost, less blood loss, less
muscle wasting, shorter operation time, and shorter
hospitalization. On the other hand, some studies have
reported that EPR is associated with higher patient sur-
vival [9], lower mechanical failure rate, and more dur-
ability than IMN [10, 11]. However, those studies did
not consider the differences in patient demographics,
and thus comparing outcomes between IMN and EPR in
these reports may not be appropriate.
Treatment indications vary between institutions.
Table 4 shows peer-reviewed articles from 2008 through
2013 and our current study, describing IMN, EPR, plat-
ing and cementation, and other surgical procedures in
femoral metastases [7–13]. These studies can be divided
into two groups. Among four studies, the proportion of
IMN/EPR is approximately 1:2 [7, 10–12]. Nilsson at al.
reported that they did not perform IMN for trochanteric
or subtrochanteric metastases [7]. Steensma et al. and
Alvi at el. avoided IMN for the patients with intertro-
chanteric lesions of the femur [11, 12]. In the other
group, the proportions of IMN and EPR were nearly
equal [8, 9, 13]. Sarahrudi et al. reported that their IMN
group included inter- and subtrochanteric metastases
[8], and Mavrogenis et al. reported also performing IMN
for fractures in the intertrochanteric part of the femur
except for metastases invading the articular surface [9].
These reports included a broader indication for IMN.
Regarding the superiority of EPR to IMN and vice versa,
while Mavrogenis at al. reported a significantly higher
survival in patients with EPR [9], Sarahrudi et al. re-
ported that EPR and IMN were equivalent in terms of
safety [8]. A few other articles have also mentioned good
outcomes with IMN [15, 16].
As far as we know, there is no strong evidence con-
cerning the indication of IMN for subtrochanteric me-
tastases. The evidence grade of EPR for femoral neck
fracture is grade B which indicates consistent, fair (level
II or III) evidence, while IMN is grade C which indicates
conflicting or poor-quality (level IV or V) evidence, in-
cluding inter- and subtrochanteric fractures, except for
intertrochanteric impending fracture whose grade is B
Fig. 3 The clinical course of one patient who undergone revision surgery after implant failure. X-ray imaging revealed an impending fracture and
an osteoblastic lesion in the left subtrochanteric part of femur (a). IMN was performed, and the postoperative course was uneventful until the implant
failure at the 50-month clinical follow-up (b). X-ray imaging showed a broken implant in proximal part (c). The IM rod was removed and the proximal
part of the femur was resected and then replaced with EPR (d)
Table 2 IMN implant failure cases
Case No. Age, sex Primary cancer Fx pattern Fx site Complication Time to failure
(months)
Treatment
1 58, F Breast Pathological Subtrochanteric Nonunion and nail breakage 4 Revision with EPR
No further complication
2 49, F Breast Impending Subtrochanteric Nail breakage 50 Revision with EPR
No further complication
3 20, F Pheochromocytoma Impending Subtrochanteric Nail breakage 11 Revision with EPR
No further complication
IMN intramedullary nailing, M male, F female, Fx fracture, EPR endoprosthetic reconstruction
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[14]. In our institution, the postoperative survival was
14.2 and 8.4 % at 2 and 3 years, respectively, and the im-
plant survival rate was 94.0 % at both 2 and 3 years.
Harvey et al. noted that the IMN implant survival rate
was 85 % at 2 years [10], and Steensma et al. noted that
the IMN implant survival rate was 88 % at 3 years [11].
Compared to these reports, our IMN implant survival
rate of 94 % at 3 years is comparable and can be
regarded as appropriate for a patient population whose
survival at 3 years is only 8.4 %.
There were three patients who underwent revisions due
to implant breakage. In all such cases, the site was in the
subtrochanteric part of the femur, and failure occurred in
the proximal part of the nail. EPR was chosen as the revi-
sion procedure in order to prevent further complications
after revision. Forsberg et al. recommended the use of
EPR as a salvage procedure even at the end of life [3], and
we concur with their recommendation.
In our study, three cases had early fatal complications
after surgery (3.8 %), all of which had lung metastases at
the time of IMN procedure. The role of IMN should be
carefully considered in patients who have pre-existing pul-
monary dysfunction. Moon et al. reported that prophylactic
IMN did not appear to be safer than curative IMN for fem-
oral fractures [18]. Barwood et al. reported that acute oxy-
gen desaturation and hypotension occurred in 24.4 % of
patients during IMN procedures for metastatic femoral
fractures and 6.6 % of patients died from cardiorespiratory
dysfunctions during the perioperative period [19].
Cost-effective treatment for bone metastases is import-
ant because of the already high cost of treating malig-
nancy [20]. Schulman et al. noted that total medical cost
for patients with bone metastases was significantly
higher than that for patients without bone metastases
[21]. A cost-effectiveness analysis between IMN and EPR
should be studied further.
Table 3 Postoperative fatal complications within 14 days
Case No. Age, sex Primary cancer Fx pattern Fx site Time to death (days) Treatment
1 78, M Melanoma Impending Proximal shaft 7 Palliative therapy
Multiple metastases: lung, liver, adrenal,
and bones
Mirels’ score 10, severe femoral pain
Cause of death: respiratory complication
2 69, M Prostate Pathological Subtrochanteric 3 Multiple metastases: lung and bones
Pathological fracture managed with
IMN insertion
Cause of death: heart dysfunction and
respiratory complication
3 48, F Lung Impending Proximal shaft 12 Palliative therapy
Multiple metastases: brain and bones
Mirels score 10, severe femoral pain
Cause of death: respiratory complications
M male, F female, Fx fracture, IMN intramedullary nailing
Table 4 Previous reports regarding surgical procedures for femoral metastatic lesions
Study Number of case IMN EPR Plating and cementation Other
procedure
Result (reoperation, complication)
Nilsson at al. [7] 2008 245 55 (22.4 %) 157 (64.1 %) 30 (12.2 %) 3 (1.2 %) Reoperation: 1.8 % IMN, 9.1 % ORIF
Sarahrudi et al. [8] 2009 139 94 (67.6 %) 23 (16.5 %) 15 (10.8 %) 7 (5.1 %) Complication: 3.2 % IMN, 8.6 % EPR,
20 % ORIF
Mavrogenis et al. [9] 2011 110 53 (48.2 %) 57 (51.8 %) – – Complication: 1.9 % IMN, 8.8 % EPR
Weiss et al. [13] 2013 196 108 (55.1 %) 82 (41.8 %) – 6 (3.1 %) Reoperation: 9.3 % IMN, 6.1 % ORIF
Harvey at al. [10] 2012 159 46 (28.9 %) 113 (71.1 %) – – Reoperation: 26.1 % IMN, 8.0 % EPR
Revision: 21.7 % IMN, 2.7 % EPR
Steensma at al. [11] 2012 298 82 (27.5 %) 197 (66.1 %) 19 (6.4 %) – Reoperation: 6.1 % IMN, 3.0 % EPR,
42.1 % ORIF
Alvi at al. [12] 2013 53 16 (30.2 %) 36 (67.9 %) 1 (1.9 %) – Revision: 35.6 % IMN
Current study 186 80 (43.0 %) 95 (51.1 %) 8 (4.3 %) 3 (1.6 %) Revision: 3.8 % IMN
IMN intramedullary nailing, EPR endoprosthetic reconstruction, ORIF open reduction and internal fixation
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Conclusions
In this report, the performance of IMN with much
broader indication including the trochanteric part of the
femur is sufficient for a few years. IMN has several advan-
tages for patients with femoral metastatic fractures, such
as lower cost, less invasiveness, wider indication, sufficient
durability, and revision options. Therefore, other than
EPR, IMN is a suitable procedure for patients with fem-
oral metastatic fracture even in trochanteric part.
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